The subject invention relates to fluid management systems.
Systems have been proposed to automatically measure the fluid delivered to a patient and fluids expelled or taken from a patient.
U.S. Pat. No. 4,291,692, for example, discloses and IV drop counter, a urine drop counter, and a microcomputer controlling an infusion pump. U.S. Pat. No. 7,029,456 discloses a “networked” system with no less than four separate units. See also U.S. Pat. No. 4,994,026 disclosing separate load scales and a control unit primarily used for dialysis.
In a cath lab, for example, a patient has a contrast agent injected into his veins, the patient's vessels are imaged, and a therapy is administered, e.g., a stent or the like is inserted into the patient. After this procedure, the contrast agent will collect in the patient's kidneys. The toxic nature of these contrast agents are well documented as is contrast nephropathy. See corresponding application Ser. No. 10/936,945 published as Published Patent Application No. 2006/0052764 incorporated herein by this reference.
Also, during cardiac surgery, the patient may be administered a fair amount of fluid. After surgery, a diuretic may be administered and the nurse instructed to allow the patient to expel urine at a rate greater than fluid administered to the patient (e.g., drugs, nutritional supplements, saline, sodium bicarbonate, and the like). Managing this prescribed fluid balance can be difficult and time consuming.
Accordingly, it is desirable to hydrate the patient sufficiently to encourage the patient to urinate and expel the toxic contrast agent and also to infuse the patient with fluid to balance the urine expelled by the patient with the fluid infused into the patient so that the patient does not become dehydrated.
But, the cath lab and other surgical and recovery sites are too small and crowded to accommodate separate urine drop counters, weight scales, or “networked” units. Moreover, the attending nurses do not have the time to learn complex systems. This is perhaps why the proposed systems of the prior art have not been commercially successful.
It is therefore an object of the invention to provide a new automated fluid replacement device. In one preferred embodiment, the new fluid replacement device is self-contained. The device also automatically takes into account fluid taken by the patient from multiple sources. The device has a user friendly interface where the nurse can enter different settings and a display which provides the information the nurse needs. Once the desired settings are entered, the device operates automatically.
It is a further object of the invention, in one example, to provide a device which can automatically provide therapy, even when, for example, a patient's urine output is less than the amount of fluid infused into the patient.
A fluid replacement device in accordance with an example of the invention includes a console with a weighing subsystem responsive to a first fluid source and a urine collection chamber, and a pump configured to pump fluid from the first fluid source into a patient. A processing subsystem in the console is responsive to the weighing subsystem and is configured to determine, based on the weight of the first fluid source and the weight of the urine collection chamber, the patient's urine output and the amount of fluid infused into the patient from the first fluid source. The processing subsystem is further configured to control the pump to adjust the operation of the pump based on the patient's urine output and the amount of fluid infused into the patient. A user interface in the console allows the user to set a desired fluid balance for the patient and to set an amount of at least one additional fluid delivered to the patient. The processing subsystem is responsive to these settings and is further configured to automatically calculate the patient's actual fluid balance based on the determined urine output, the determined amount of fluid infused into the patient from the first fluid source, and the set amount of the at least one additional fluid delivered to the patient. The pump is controlled based on the actual fluid balance and the set desired fluid balance until the actual fluid balance is the same as or approximately the same as the desired fluid balance.
The typical user interface includes a display and the processing subsystem may be configured to display the actual fluid balance, the set desired fluid balance, the determined urine output, the determined amount of fluid infused into the patient, and the set amount of the at least one additional fluid delivered to the patient.
The processing subsystem may further be configured to automatically detect when the determined urine output is less than a set fluid balance. In response, the processing subsystem controls the pump to infuse a minimum preset amount of fluid from the source of fluid. The processing subsystem can also automatically detect when the determined urine output is greater than the total of the determined amount of fluid infused into the patient and the set amount of the at least one additional fluid delivered to the patient and, in response, it controls the pump to infuse fluid from the first source of fluid until the actual fluid balance equals or approximates the set desired fluid balance.
In one version, there are means for setting an amount of at least one additional fluid expelled by the patient. The processing subsystem is responsive to this setting and is configured to calculate an actual fluid balance based on the determined urine output, the determined amount of fluid infused into the patient from the first fluid source, the set amount of the at least on additional fluid delivered to the patient, and the set amount of the at least one additional fluid expelled by the patient.
There may also be means for setting a bolus amount of fluid to be injected into the patient from the first fluid source. Then, the processing subsystem is further configured to be responsive to the set bolus amount and to control the pump until the actual fluid balance is the same as or approximately the same as the set bolus amount.
One novel fluid replacement device comprises a console including a pump infusing fluid from a first fluid source into a patient, and a processing subsystem configured to determine the patient's urine output and the amount of fluid infused into the patient from the first fluid source. The processing subsystem is also configured to control the pump to adjust the operation of the pump based on the patient's urine output and the amount of fluid infused into the patient. A user interface in the console allows the user to set a desired fluid balance for the patient and set an amount of at least one additional fluid delivered to the patient. The processing subsystem is responsive to these setting and automatically calculates the actual fluid balance based on the determined urine output, the determined amount of fluid infused into the patient from the first fluid source, and the set amount of the at least one additional fluid delivered to the patient. The pump is controlled based on the actual fluid balance and the set desired fluid balance until the actual fluid balance is the same as or approximately the same as the desired fluid balance.
The subject invention also features a fluid replacement method. The amount of urine expelled by a patient is determined. Fluid from a first fluid source is infused into a patient. The amount of fluid infused into the patient from the first fluid source is determined. The operation of the pump is adjusted based on the patient's urine output and the amount of fluid infused into the patient.
A desired fluid balance for the patient can be set. An amount of at least one additional fluid delivered to the patient can be input. An actual fluid balance is calculated based on the determined urine output, the determined amount of fluid infused into the patient from the first fluid source, and the set amount of the at least one additional fluid delivered to the patient. The pump is controlled based on the actual fluid balance and the set desired fluid balance until the actual fluid balance is the same as or approximately the same as the desired fluid balance.
Urine expelled by the patient may be collected in a urine collection bag and determining the amount of urine expelled by the patient may including weighing the collection bag. Also, determining the amount the fluid infused into the patient from the first fluid source may include weighing the first fluid source. The actual fluid balance, the set desired fluid balance, the determined urine output, the determined amount of fluid infused into the patient, and the set amount of at least one additional fluid delivered to the patient are all quantities which are typically displayed.
The method may further include detecting when the determined urine output is less than a set fluid balance and, in response, controlling the pump to automatically infuse a minimum preset amount of fluid from the source of fluid. The method may further include detecting when the determined urine output is greater than the total of the determined amount of fluid infused into the patient and the set amount of the at least one additional fluid delivered to the patient and, in response, controlling the pump to automatically infuse fluid from the source of fluid until the actual fluid balance equals or approximates the set desired fluid balance.
The method may further include setting an amount of at least one additional fluid expelled by the patient and calculating an actual fluid balance based on the determined urine output, the determined amount of fluid infused into the patient from the first fluid source, the set amount of the at least one additional fluid delivered to the patient, and the set amount of the at least one additional fluid expelled by the patient.
The method may further include setting a bolus amount of fluid to be infused into the patient from the fluid source and automatically controlling the pump until the actual fluid balance is the same as or approximately the same as the set bolus amount.
The subject invention, however, in other embodiments, need not achieve all these objectives and the claims hereof should not be limited to structures or methods capable of achieving these objectives.
Other objects, features and advantages will occur to those skilled in the art from the following description of a preferred embodiment and the accompanying drawings, in which:
Aside from the preferred embodiment or embodiments disclosed below, this invention is capable of other embodiments and of being practiced or being carried out in various ways. Thus, it is to be understood that the invention is not limited in its application to the details of construction and the arrangements of components set forth in the following description or illustrated in the drawings. If only one embodiment is described herein, the claims hereof are not to be limited to that embodiment. Moreover, the claims hereof are not to be read restrictively unless there is clear and convincing evidence manifesting a certain exclusion, restriction, or disclaimer.
Fluid replacement system 10,
Pump 18 is configured to pump fluid from source 16 into a patient as shown. Pump 18 is controlled by processing subsystem 20, e.g., a computer, a field programmable gate array, application specific integrated circuit, microprocessor, controller, or the like.
Processing subsystem 20 is configured to be responsive to weighing subsystem 12 and is configured (e.g., programmed) to determine, based on the weight of fluid source 16, the amount of fluid infused into the patient over some interval (e.g., an hour). Processing subsystem 20 may also monitor the operation history of pump 18 to determine the amount of fluid infused into the patient from source 16. Other means for determining the amount of fluid infused into the patient are within the scope of the subject invention. Processing subsystem 20 further determines, based on the weight of urine collection chamber 14, the patient's urine output over some interval. Other means for determining urine output are possible. The programming associated with processing subsystem 20 then typically controls pump 18 to adjust the operation of pump 18 based on the patient's urine output and the amount of fluid infused into the patient (e.g., manually or from other infusion pumps, IV drops, and the like).
There are also means for setting a desired fluid balance for a given patient and for setting an amount of at least one additional fluid delivered to the patient. Such means may include user interface 22 (e.g., a monitor and keyboard or touch screen). As shown, the set desired balance may be stored in memory 24 associated with processing subsystem 20 and a set amount of the at least one additional fluid delivered to the patient (“other intake”) may also be stored in memory 24. Memory 24 can also be used to store default values for various parameters.
Processing subsystem 20 includes programming which takes these parameters as inputs and calculates an actual patient fluid balance based on the determined urine output, the determined amount of fluid infused into the patient from the first fluid source, and the set amount of the at least one additional fluid delivered to the patient by other means. Processing subsystem 20 controls pump 18 based on the actual fluid balance and the set desired fluid balance until the actual fluid balance is the same as or approximately the same as the desired fluid balance.
The result is a stand alone integrated device which can be coupled to N pole 42 and moved with the patient when he leaves the cath lab as opposed to multiple units wired together or “networked” units.
Processing subsystem 20,
Then, processing subsystem 20,
In step 112,
In the second hour, the patient's urine output is 200 ml but the amount infused is only about 25 ml and again, the set fluid received by the patient from another source is about 100 ml. Processing subsystem 20,
Although specific features of the invention are shown in some drawings and not in others, this is for convenience only as each feature may be combined with any or all of the other features in accordance with the invention. The words “including”, “comprising”, “having”, and “with” as used herein are to be interpreted broadly and comprehensively and are not limited to any physical interconnection. Moreover, any embodiments disclosed in the subject application are not to be taken as the only possible embodiments.
In addition, any amendment presented during the prosecution of the patent application for this patent is not a disclaimer of any claim element presented in the application as filed: those skilled in the art cannot reasonably be expected to draft a claim that would literally encompass all possible equivalents, many equivalents will be unforeseeable at the time of the amendment and are beyond a fair interpretation of what is to be surrendered (if anything), the rationale underlying the amendment may bear no more than a tangential relation to many equivalents, and/or there are many other reasons the applicant can not be expected to describe certain insubstantial substitutes for any claim element amended.
Other embodiments will occur to those skilled in the art and are within the following claims.
This application is a divisional of U.S. patent application Ser. No. 16/053,056 filed Aug. 2, 2018, now U.S. Pat. No. 11,064,939, which is a divisional of U.S. patent application Ser. No. 12/657,144 filed Jan. 14, 2010, now U.S. Pat. No. 10,045,734, and claims the benefit of and priority to U.S. Provisional Application No. 61/206,254, filed on Jan. 28, 2009.
Number | Name | Date | Kind |
---|---|---|---|
3954010 | Hilblom | May 1976 | A |
4132644 | Kolberg | Jan 1979 | A |
4146029 | Ellinwood, Jr. | Mar 1979 | A |
4204957 | Weickhardt | May 1980 | A |
4216462 | McGrath et al. | Aug 1980 | A |
4229299 | Savitz et al. | Oct 1980 | A |
4261360 | Perez | Apr 1981 | A |
4275726 | Schael | Jun 1981 | A |
4291692 | Bowman et al. | Sep 1981 | A |
4343316 | Jespersen | Aug 1982 | A |
4448207 | Parrish | May 1984 | A |
4449538 | Corbitt et al. | May 1984 | A |
4504263 | Steuer et al. | Mar 1985 | A |
4658834 | Blankenship et al. | Apr 1987 | A |
4712567 | Gille et al. | Dec 1987 | A |
4728433 | Buck et al. | Mar 1988 | A |
4813925 | Anderson, Jr. et al. | Mar 1989 | A |
4923598 | Schal | May 1990 | A |
4994026 | Fecondini | Feb 1991 | A |
5098379 | Conway et al. | Mar 1992 | A |
5176148 | Wiest et al. | Jan 1993 | A |
5207642 | Orkin et al. | May 1993 | A |
5573506 | Vasko | Nov 1996 | A |
5722947 | Jeppsson et al. | Mar 1998 | A |
5769087 | Westphal et al. | Jun 1998 | A |
5814009 | Wheatman | Sep 1998 | A |
5891051 | Han et al. | Apr 1999 | A |
5910252 | Truitt et al. | Jun 1999 | A |
5916153 | Rhea, Jr. | Jun 1999 | A |
5916195 | Eshel et al. | Jun 1999 | A |
5981051 | Motegi et al. | Nov 1999 | A |
5984893 | Ward | Nov 1999 | A |
6010454 | Arieff et al. | Jan 2000 | A |
6171253 | Bullister et al. | Jan 2001 | B1 |
6231551 | Barbut | May 2001 | B1 |
6272930 | Crozafon | Aug 2001 | B1 |
6514226 | Levin et al. | Feb 2003 | B1 |
6531551 | Ohno et al. | Mar 2003 | B2 |
6537244 | Paukovits et al. | Mar 2003 | B2 |
6554791 | Cartledge et al. | Apr 2003 | B1 |
6640649 | Paz et al. | Nov 2003 | B1 |
6740072 | Starkweather et al. | May 2004 | B2 |
6752779 | Paukovits et al. | Jun 2004 | B2 |
6796960 | Cioanta et al. | Sep 2004 | B2 |
6827702 | Lebel et al. | Dec 2004 | B2 |
6942637 | Cartledge et al. | Sep 2005 | B2 |
7029456 | Ware et al. | Apr 2006 | B2 |
7044002 | Ericson et al. | May 2006 | B2 |
7137964 | Flaherty | Nov 2006 | B2 |
7278983 | Ireland et al. | Oct 2007 | B2 |
7727222 | Da Silva et al. | Jun 2010 | B2 |
7736354 | Gelfand et al. | Jun 2010 | B2 |
7758562 | Gelfand et al. | Jul 2010 | B2 |
7758563 | Gelfand et al. | Jul 2010 | B2 |
7837667 | Gelfand et al. | Nov 2010 | B2 |
8075513 | Rudko et al. | Dec 2011 | B2 |
8444623 | Gelfand et al. | May 2013 | B2 |
11064939 | Da Silva et al. | Jul 2021 | B2 |
20020025597 | Matsuda | Feb 2002 | A1 |
20020072647 | Schock et al. | Jun 2002 | A1 |
20020107536 | Hussein | Aug 2002 | A1 |
20020151834 | Utterberg | Oct 2002 | A1 |
20020161314 | Sarajarvi | Oct 2002 | A1 |
20030048185 | Citrenbaum et al. | Mar 2003 | A1 |
20030048432 | Jeng et al. | Mar 2003 | A1 |
20030114786 | Hiller et al. | Jun 2003 | A1 |
20040025597 | Ericson et al. | Feb 2004 | A1 |
20040059295 | Cartledge et al. | Mar 2004 | A1 |
20040081585 | Reid | Apr 2004 | A1 |
20040087894 | Flaherty | May 2004 | A1 |
20040122353 | Shahmirian et al. | Jun 2004 | A1 |
20040133187 | Hickle | Jul 2004 | A1 |
20040163655 | Gelfand et al. | Aug 2004 | A1 |
20040167415 | Gelfand et al. | Aug 2004 | A1 |
20040167464 | Ireland et al. | Aug 2004 | A1 |
20040176703 | Christensen et al. | Sep 2004 | A1 |
20040193328 | Zaitsu et al. | Sep 2004 | A1 |
20040243075 | Harvie | Dec 2004 | A1 |
20050027254 | Vasko | Feb 2005 | A1 |
20050065464 | Talbot et al. | Mar 2005 | A1 |
20050085760 | Ware et al. | Apr 2005 | A1 |
20060052764 | Gelfand et al. | Mar 2006 | A1 |
20060064053 | Bollish et al. | Mar 2006 | A1 |
20060184084 | Ware et al. | Aug 2006 | A1 |
20060235353 | Gelfand et al. | Oct 2006 | A1 |
20060253064 | Gelfand et al. | Nov 2006 | A1 |
20060270971 | Gelfand et al. | Nov 2006 | A1 |
20070088333 | Levin et al. | Apr 2007 | A1 |
20080027409 | Rudko et al. | Jan 2008 | A1 |
20080033394 | Gelfand et al. | Feb 2008 | A1 |
20080171966 | Rudko et al. | Jul 2008 | A1 |
20080221512 | Da Silva et al. | Sep 2008 | A1 |
20100234797 | Gelfand et al. | Sep 2010 | A1 |
20100280443 | Gelfand et al. | Nov 2010 | A1 |
20100280444 | Gelfand et al. | Nov 2010 | A1 |
20100280445 | Gelfand et al. | Nov 2010 | A1 |
20110046516 | Paz et al. | Feb 2011 | A1 |
20120259308 | Gelfand et al. | Oct 2012 | A1 |
Number | Date | Country |
---|---|---|
0258690 | Mar 1998 | EP |
2008110150 | May 2008 | JP |
1996016685 | Jun 1996 | WO |
1996028209 | Sep 1996 | WO |
1997016220 | May 1997 | WO |
1999006087 | Feb 1999 | WO |
2006041496 | Apr 2006 | WO |
Entry |
---|
Angiometrx, The Metricath System, http://www.angiometrx.com/Metricath%20System.htm (Jul. 6, 2005) (one (1) page). |
Bard Lubricath 3-Way Catheters, Bard Medical Division, http://www/bardmedical.com/uroloogy/cathtour/3way.html (Jul. 6, 2005) (one (1) page). |
Bart et al., “Ultrafiltration in Decompensated Heart Failure With Cardiorenal Syndrome”, The New England Journal of Medicine, Dec. 13, 2012, pp. 2296-2304, Massachusetts Medical Society. |
Brezis et al., Hypoxia of the Renal Medulla—Its Implications for Disease, New England Journal of Medicine, vol. 322, No. 10, Mar. 9, 1995, pp. 647-655 (nine (9) pages). |
Briguori et al., “Renal Insufficiency After Contrast Media Administration Trial II (Remedial II): RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury”, Circulation, Journal of the American Heart Association, Mar. 13, 2011, pp. 1-10. |
Dorval et al., “Feasibility Study of the RenalGuard™ Balanced Hydration System: A Novel Strategy for the Prevention of Contrast-Induced Nephropathy in High Risk Patients”, International Journal of Cardiology, 2011, pp. 1-5, Elsevier Ireland Ltd. |
Doty et al., Effect of Increased Renal Venous Pressure on Renal Function, The Journal of Trauma: Injury, Infection and Critical Care, vol. 47, No. 6, Dec. 1999, pp. 1000-1003 (four (4) pages). |
Edelson et al., Pharmacokinetics of Iohexol, a New Nonionic Radiocontrast Agent, in Humans, Journal of Pharmaceutical Sciences, vol. 73, No. 7, Jul. 1984, pp. 993-995 (three (3) pages). |
Felker et al., “Diuretic Strategies in Patients With Acute Decompensated Heart Failure”, The New England Journal of Medicine, Mar. 3, 2011, vol. 364, No. 9, pp. 797-805. |
Foley Catheter Introduction, Foley Catheter, http://www/wmedicinehealth.com/articles/11633-1.asp; http://www.emedicinehealth.com/articles/11633-8.asp (Jul. 6, 2005) (two (2) pages). |
Gambro Acute Renal Failure, Prisma, http://www.gambro.com/Page.asp?id=2446; http://www.gambro.com/upload/press_media_toolkit/download_images/Prisma.jpg (Jul. 6, 2005) (two (2) pages. |
Gloor, James M. and Vincente E. Torres, Reflux and Obstructive Nephropathy, Atlas of Diseases of the Kidney, on-line edition, vol. Two, Section I, Ch. 8, pp. 8.1-8.25 (date unknown) (twenty-five (25) pages). |
Heyman et al., Pathophysiology of Radiocontrast Nephropathy: A Role for Medullary Hypoxia, Investigative Radiology, vol. 34, No. 11, Nov. 1999, pp. 685-691 (seven (7) pages). |
Hvistendahl et al., Renal Hemodynamic Response to Gradated Ureter Obstruction in the Pig, Nephron 1996, 74:168-74 (seven (7) pages). |
Infusion Dynamics: Power Infuser, The Power Infuser, http://www.infusiondynamics.com/powerinfuser/ (Apr. 4, 2005) (two (2) pages). |
Lelarge et al., Acute Unilateral Renal Failure and Contralateral Ureteral Obstruction, American Journal of Kidney Diseases, vol. XX, No. 3, Sep. 1992, pp. 286-288 (three (3) pages). |
Levin et al. High-volume diuresis with matched maintenance of intravascular volume may prevent contrast-induced nephropathy in post-transplant patients with moderate-severe baseline renal impairment, Cardiovascular Revascularization Medicine, Elsevier, NL, vol. 8, No. 2, Apr. 1, 2007, p. 153 (one (1) page). |
Lloyd-Jones et al., “Heart Disease and Stroke Statistics—2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee”, Circulation, Journal of the American Heart Association, Jan. 27, 2009, pp. e21-e181 and Correction sheet e424. |
Marenzi et al.. “Prevention of Contrast Nephropathy by Furosemide With matched Hydration. The MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) Trial”, JACC: Cardiovascular Interventions, vol. 5, No. 1, 2012 The American College of Cardiology Foundation, pp. 90-97. |
Mawer et al., “Value of Forced Diuresis in Acute Barbiturate Poisoning”, Jun. 29, 1968, British Medical Journal, 2, 790-793. |
Merit Medical Systems, Inc., 2003 Annual Report; Balloon Inflation Devices & Pressure Monitoring Syringes; Transducers and Accessories, http://www.corporatewindow.com/annuals/mmsi03/10kpages5.html (Jul. 6, 2005) (three (3) pages). |
Millar Instruments: Single Sensor Cardiology Catheters, Cardiovascular Mikro-Tip Pressure Transducer Catheters, http://www.millarinstruments.com/products/cardio/cardio_sngldual.html (Jul. 6, 2005) (five (5) pages). |
Paterna et al., “Changes in Brain Natriuretic Peptide Levels and Bioelectrical Impedance Measurements After Treatment With High-Dose Furosemide and Hypertonic Saline Solution Versus High-Dose Furosemide Alone in Refractory Congestive Heart Failure”, Journal of the American College of Cardiology, 2005, vol. 45, No. 12, pp. 1997-2003. |
Pederson et al., Renal Water and Sodium Handling During Gradated Unilateral Ureter Obstruction, Scand J. Urol Nephrol, 2002, 36:163-72 (ten (10) pages). |
Rihal et al., Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention, Circulation, May 14, 2002, pp. 2259-2264 (six (6) pages). |
Rosamilia et al., Electromotive Drug Administration of Lidocaine and Dexamethasone Followed by Cystodistension in Women with Interstitial Cystitis, International Urogyecologyl Journal, Pelvic Floor Dysfunction 1997; 8: 142-5 (four (4) pages. |
S215 Ultra Low Profile Single Point Load Cell—Strain Guage Sensors and Load Cells, Ultra-Low Profile Single Point Load Cell—S215, http://smdsensors.com/detail_pgs/s215.htm (Apr. 4, 2005) (two (2) pages). |
Solomon et al., Effects of Saline, Mannitol, and Furosemide on Acute Decreases in Renal Function Induced by Radiocontrast Agents, The New England Journal of Medicine, vol. 331: 1416-1420, Nov. 24, 1994, No. 21 (eleven (11) pages). |
Stevens, Melissa A., MD et al., A Prospective Randomized Trial of Prevention Measures in Patients at High Risk for Contrast Nephropathy, Results of the P.R.I.N.C.E. Study, Journal of American College of Cardiology, vol. 33, No. 2, Feb. 1999, pp. 403-411 (nine (9) pages). |
Stevenson et al., “Editorial Comment, Torrent or Torment From the Tubules?”, Challenge of the Cardiorenal Connections, Journal of the American College of Cardiology, vol. 45, No. 12, 2005, pp. 2004-2007. |
Urexact® 2000 System, mhtml:file//C:\Documents%20and%20Settings\bob\Local%20Settings\Temporary%20Intt . . . (Jul. 22, 2005) (three (3) pages). |
Wakelkamp et al., The influence of drug input rate on the development of tolerance to frusemide, Br. J. Clin. Pharmacol 1998, 46:479-487, pp. 479-487 (nine (9) pages). |
Weinstein et al., Potential deleterious Effect of Furosmide in Radiocontrast Nephropathy, Department of Medicine, Hadassah Univeristy Hospital, Mount Scopus, Jerusalem, Israel, Nephron 1992, 62: 413-415 (three (3) pages). |
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2005/008948 dated Oct. 3, 2006 (five (5) pages). |
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2007/021791 dated May 8, 2008 (nine (9) pages). |
Office Action of the Canadian Intellectual Property Office for Canadian Patent Application No. 2,579,829 dated Jun. 13, 2008 (two (2) pages). |
Written Opinion of the International Searching Authority for PCT Application No. PCT/U20S07/009685 dated Jul. 18, 2008 (twelve (12) pages). |
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2007/009684 dated Jul. 21, 2008 (nine (9) pages). |
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2008/007845 dated Sep. 17, 2008 (seven (7) pages). |
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2008/007841 dated Sep. 18, 2008 (six (6) pages). |
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2007/009683 dated Nov. 24, 2008 (eight (8) pages). |
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2009/002739 dated Jun. 19, 2009 (six (6) pages). |
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2010/000137 dated Mar. 16, 2010 (eleven (11) pages). |
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2015/020196, dated Jun. 12, 2015, 5 pages. |
Number | Date | Country | |
---|---|---|---|
20210378589 A1 | Dec 2021 | US |
Number | Date | Country | |
---|---|---|---|
61206254 | Jan 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16053056 | Aug 2018 | US |
Child | 17359280 | US | |
Parent | 12657144 | Jan 2010 | US |
Child | 16053056 | US |